Home/Kyowa Kirin/Yuki Kuroda
YK

Yuki Kuroda

Senior Vice President, Corporate Strategy

Kyowa Kirin

Kyowa Kirin Pipeline

DrugIndicationPhase
Mogamulizumab (Poteligeo)Cutaneous T-cell lymphomaApproved
Burosumab (Crysvita)X-linked hypophosphatemiaApproved
Evocalcet (Orkedia)Secondary hyperparathyroidismApproved
KW-6356Atopic dermatitisPhase 2
MezagitamabB-cell malignanciesPhase 1/2
KHK4083Atopic dermatitisPhase 2
Romiplostim (Nplate)ThrombocytopeniaApproved
Darbepoetin alfaAnemiaApproved